Marpai Q3 revenue $8.7M (+77% YoY); net loss $7.3M; withdraws S-1, suspends guidance

Marpai, Inc.

2023-Q3 EPS reported -$3.62 vs consensus -$0.94 ▼ miss (-285.8%)

Total revenue $8.7M for Q3 2023, up 77% YoY, driven by acquisition of Maestro Health.
Net loss of $7.3M ($0.98 per share) vs. net loss $5.8M ($1.14 per share) in Q3 2022.
Customers' employees reached ~37,000, a 126% increase from 16,000 a year ago.
Withdrew its Form S-1 registration statement due to adverse market conditions; evaluating financing.
Suspended full-year 2023 financial guidance; company focusing on path to profitability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Marpai, Inc. reported three and nine months ended September 30, 2023 results: revenue $8.7 million, net income nearly $7.3 million, EPS ($0.98) per share.

Period: three and nine months ended September 30, 2023
Revenue: $8.7 million
Net income: nearly $7.3 million
EPS: ($0.98) per share
Result: reported results

Exact text from the filing

Health, LLC (“Maestro Health”) since its acquisition on November 1, 2022. Third Quarter 2023 Highlights: • Total revenue for the three months ended September 30, 2023 was $8.7 million, representing an increase of $3.8 million, or nearly 77%, over the same period in 2022. The primary reason for this increase was due to the revenue from the acquisition of

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Marpai, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.